Diagnostic performance and antibiotic impact of droplet digital PCR in suspected sepsis: the PROGRESS trial.

Summary

In the prospective multicenter PROGRESS randomized trial, 1,373 patients with suspected sepsis were assigned in a 3:1 ratio to droplet digital PCR or standard care and followed for 90 days. Droplet digital PCR produced a markedly higher pathogen-detection positivity rate than standard care, directly addressing the diagnostic and antibiotic-management limitations of conventional testing.

Key Findings

• The prospective multicenter randomized trial enrolled 1,373 patients with suspected sepsis and followed them for 90 days.
• Patients were randomized in a 3:1 ratio to droplet digital PCR or standard care.
• Pathogen-detection positivity was higher with droplet digital PCR than with standard care: 54.1% versus 21.6%, respectively.

Clinical Implications

Droplet digital PCR may support faster and more sensitive pathogen detection and could help clinicians refine antimicrobial selection or de-escalation. Before routine implementation, effects on antibiotic exposure, mortality, costs, turnaround time, and performance across different laboratories and pathogen spectra should be confirmed.

Limitations

• The provided abstract does not report the full effects on mortality, SOFA score, antibiotic exposure, or antibiotic adjustment.
• The abstract does not provide detailed information on blinding, allocation concealment, pathogen-specific performance, or laboratory implementation requirements.

Future Directions

Future studies should report antibiotic de-escalation, time to effective therapy, antimicrobial resistance, costs, and patient-centered outcomes. Independent implementation trials across hospitals with different microbiology infrastructure are needed to determine whether improved detection translates into better survival or antibiotic stewardship.